HIV pre‐exposure prophylaxis (PrEP), the use of HIV treatment medication by people at risk of HIV to reduce their risk of acquisition, has emerged over recent years as a highly‐effe­ctive HIV …

eXpanded (PrEPX) is a new study that will expand the provision of PrEP to 3,200 Victorians who have a high chance of acquiring HIV. Alfred Health is responsible for conducting the study.

Jul 26, 2016 · The PrEPX Study enrolled over 5,000 participants between 2016 and 2018 in Victoria, South Australia and Tasmania. Participants were at risk of HIV infections and …

PrepX is an AI-powered platform for practicing English tests like PTE, IELTS, and more. Improve your skills with personalized exercises, instant feedback, and comprehensive study resources.

The PrEPX study sought to provide PrEP to 2600 people at high risk of HIV in Victoria, Australia, with the primary aim of reducing HIV transmissions in Victorian MSM by 30% and in the entire …

Background: Pre-exposure prophylaxis (PrEP) is the use of HIV anti-retroviral therapy to prevent HIV transmission in people at high risk of HIV acquisition. PrEP is highly efficacious when …

WHO defines pre-exposure prophylaxis (PrEP) as the use of oral tenofovir disoproxil fumarate (TDF) or co-formulated TDF/emtricitabine (TDF/FTC) or co-formulated TDF/lamivudine …

May 29, 2018 · PrEPX is a prospective, population-level intervention study, designed to emulate “real world” conditions to reflect the likely clinical scenario were tenofovir and emtricitabine to …

Australia is considered to be a leading country in the provision of PrEP to populations at risk of HIV infection. The current national HIV strategy includes an aim of increasing to 75% the …

The PrEPX study was an Australian demonstration study of daily PrEP conducted in Victoria, South Australia, and Tasmania, which enrolled over 5000 participants between July 2016 and …